4BIO Capital is proud to announce that EG Life Sciences Fund I Ltd (EGLSF 1, or the “Fund”), has won two industry awards at the 2018 EuroHedge Emerging Fund Management Awards Ceremony, in recognition of the fund’s strong performance since launch.
EGLSF 1 won the Award for Best Performing Fund since inception in the Global Equities Category as well as the Best Performing New Fund with Assets under Management below US$ 500 million. 4BIO Capital acts as an advisor to the Fund.
As of 31 August 2018, the Fund had demonstrated returns of 53.3% in the year to date or 90.4% on an annualised basis. That compares with a return of around 14.48% on the Nasdaq Biotech Index (“NBI”) over the same period. Since inception, the Fund has delivered a return of nearly 77.4%.
The EuroHedge Emerging Fund Management Awards honour the best performing smaller and more recently launched absolute return funds based in Europe. The key criteria are performance and Sharpe ratio. This reflects the industry’s twin objectives of delivering high returns and superior risk management.